- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03234127
Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia (SAFIR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of the SAFIR study is to perform non-invasive coronary vascular phenotyping of familial hypercholesterolemia (FH) families by performing a coronary calcium score and then to detect protective genetic factors in patients who do not have a significant atheroma despite a perturbed biological phenotype.
The investigators will also conduct biochemical, lipidemic and metabolomic analyzes to identify a signature of biomarkers protective of cardiovascular risk in FH patients.
The investigators will use the French FH register, which already includes 3889 patients, to identify these "protected" FH families within the main reference centers for the management of FH for inclusion and follow-up of patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dijon, France, 29079
- Le Bocage Hospital
-
Lille, France, 59037
- CHRU de Lille
-
Lyon, France, 69677
- Louis Pradel cardiovascular Hospital
-
Marseille, France, 13285
- La Conception Hospital
-
Nantes, France, 44093
- Nantes University Hospital
-
Paris, France, 75013
- Pitie-Salpêtrière Hospital
-
Paris, France, 75012
- Saint-Antoine Hospital
-
Rennes, France, 35033
- Rennes University Hospital
-
Toulouse, France, 31059
- Toulouse Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient agreeing to sign the consent of the study and the consent of biocollection
- Patient suffering from a familial hypercholesterolemia with a clinically-biologic score DLCN (Dutch Lipid Clinic Network, Annex 2)> 8 and / or a causative mutation identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.
- Men ≥ 40 years of age; Female ≥ 50 years
- Patient affiliated to an existing social insurance
The inclusion criteria to be met in the population with known coronary atheroma:
- Subject in secondary prevention of an atheromatous disease: coronary event or ischemic heart disease, irrespective of the result of the coronary calcium score; Ischemic stroke with proven carotid atheromatosis; revascularization (angioplasty, bypass surgery) or amputation in PAD
- Primary prevention topic CV with calcium score ≥ 400 Agatston units
Inclusion criteria to be met in the population without cardiovascular risk:
- No cardiovascular event (including MI, coronary revascularization, angina, stroke &, Transiant ischemic attack of atheromatous origin, PAD) with: For women between 50 and 65 years, a nil calcium score * For women between 65 and 75 years of age, a calcium score** ≤ 10 Agatston units For women over 75 years of age, a calcium score** ≤ 20 Agatston units For men between 40 and 55 years of age, a nil calcium score* for men For men between 55 and 70 years of age, a calcium score** ≤ 10 Agatston units For men over 70 years of age, a calcium score** ≤ 20 Agatston units
- 40 year old men and 50 year old women: less than 6 months old
- 41 year old men and 51 year old women: under 1 year old
- 42 year old men and 52 year old women: under 2 years old
- 43 year old men and 53 year old women: under 3 years old
44 year old men and 54 year old women: under 4 years old
- Less than 5 years
Inclusion criteria to be met in the related population with familial hypercholesterolemia :
- Patient agreeing to sign the consent of the study and the consent of biocollection
- Patient suffering from a familial hypercholesterolemia with a clinically-biologic score DLCN (Dutch Lipid Clinic Network, Annex 2)> 8 and / or a causative mutation identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.
- Men or Female ≥ 30 years
- Patient affiliated to an existing social insurance
Inclusion criteria to be met in the related population without familial hypercholesterolemia :
- Patient agreeing to sign the consent of the study and the consent of biocollection
- Patient not suffering from a familial hypercholesterolemia related to one of the members of the population suffering from familial hypercholesterolemia without cardiovascular risk
- Men or Female ≥ 18 years
- Patient affiliated to an existing social insurance
Exclusion Criteria:
- Subject suffering from active cancer or progressive neoplasia
- Subject treated with recent corticosteroid therapy
- Subjects with unsubstituted or poorly controlled hypothyroidism (TSH> normal)
- Subject receiving immunosuppressive or anti-cancer treatment
- Subject refusing to participate
- Subjects under tutelage, curatorship or a safeguard of justice or without social insurance
The exclusion criterion for all populations except the related population without familial hypercholesterolemia:
- Subject with no "definite" familial hypercholesterolemia according to the DLCN score (≤8), after auction. The purpose of the auction will be to rule on the causal nature of an identified mutation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Atherosclerosis- resistance
FH Patient without atherosclerosis
|
Whole Genome Sequencing Biomarkers analyses
Other Names:
|
Other: Control
FH patient with atheroclerosis
|
Whole Genome Sequencing Biomarkers analyses
Other Names:
|
Other: the related population without familial hypercholesterolemia
No FH patient
|
Whole Genome Sequencing Biomarkers analyses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of genes associated with the resistance to development of coronary atherosclerosis in subjects with heterozygous familial hypercholesterolemia
Time Frame: 3 years
|
Identification of functional genetic variants by a Whole Genome Sequencing (WGS) approach in case-control analysis (FH without and with advanced coronary atherosclerosis) and/or family analysis (protected and affected relatives)
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of new biochemical, lipidemic, metabolomic and metagenomic biomarkers associated with cardiovascular protection in FH patients.
Time Frame: 3 years
|
Lipidic panel, phosphocalcic panel, Ceramides, Alipoproteins, Lp(a), lipidomic, LDL size, Phospholipids, TMAO, Carnitin, Cholin, microbiota, metabolomic, LDL Ox, Sterols, Isoprostan, oxidation, inflammation, cytokins, oxidative stress.
|
3 years
|
Association of arterial stiffness (reflected by the pulse wave velocity) with the development of coronary atherosclerosis in FH patients
Time Frame: 3 years
|
Measurement of arterial stiffness measured by popmeter® (pulse wave velocity)
|
3 years
|
Association of atherosclerosis of supra-aortic trunks (AST) with the development of coronary atherosclerosis in FH patients
Time Frame: 3 years
|
Measurement of ASD through arterial Doppler ultrasonography (Intra-media thickness (IMT), degree of stenosis (ESCT), plaque)
|
3 years
|
Association of atherosclerosis of the lower limbs with the development of coronary atherosclerosis (PAD) in FH patients
Time Frame: 3 years
|
Measurement of lower extremity involvement by arterial doppler ultrasonography
|
3 years
|
Association between aortic valvular score and development of coronary atherosclerosis in FH patients
Time Frame: 3 years
|
Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan
|
3 years
|
Association between coronary calcium score and aortic valvular score in HF patients
Time Frame: 3 years
|
Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC17_0244
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Homozygous Familial Hypercholesterolemia
-
Novartis PharmaceuticalsActive, not recruitingFamilial Hypercholesterolemia - HomozygousGreece, Lebanon, Turkey, France, Canada, Malaysia, Netherlands, United States
-
Novartis PharmaceuticalsRecruitingHeterozygous or Homozygous Familial HypercholesterolemiaNetherlands, Israel, Hungary, Italy, Germany, Spain, France, Norway, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, United States, Russian Federation, Taiwan
-
REGENXBIO Inc.National Heart, Lung, and Blood Institute (NHLBI)TerminatedHomozygous Familial Hypercholesterolemia (HoFH)United States, Canada, Italy, Netherlands
-
Institut Investigacio Sanitaria Pere VirgiliRecruitingFamilial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | Familial Hypercholesterolemia - HeterozygousSpain
-
Novartis PharmaceuticalsCompletedElevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVDUnited States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingHomozygous Familial HypercholesterolemiaChina
-
Beijing Suncadia Pharmaceuticals Co., LtdNot yet recruitingHomozygous Familial Hypercholesterolemia
-
Arrowhead PharmaceuticalsActive, not recruitingHomozygous Familial HypercholesterolemiaAustralia, Canada, United States, South Africa
-
AkesoAD Pharmaceuticals Co., Ltd.CompletedHomozygous Familial HypercholesterolemiaChina
Clinical Trials on Whole Genome Sequencing
-
Children's Hospital of Fudan UniversityNot yet recruitingDiarrhea, Infantile | Enteropathy
-
Thomas Jefferson UniversityRecruitingGenetic Disorders | Nonimmune Fetal Hydrops | Nonimmune Hydrops in NeonateUnited States
-
Boston Children's HospitalNational Eye Institute (NEI)RecruitingStrabismus | Nystagmus, CongenitalUnited States
-
Institut National de la Santé Et de la Recherche...Hospices Civils de Lyon; University Hospital, Rouen; Centre Hospitalier Universitaire... and other collaboratorsActive, not recruitingIntellectual DisabilityFrance
-
Nantes University HospitalAXA Assurances VIE MutuelleNot yet recruitingSudden Infant Death | Sudden Unexplained Infant DeathFrance
-
University of CambridgeIllumina, Inc.; Rosetrees Trust; Isaac Newton Trust; NIHR Cambridge Biomedical...Recruiting
-
Istituto Superiore di SanitàFondazione G.B. Bietti, IRCCS; Ospedale Pediatrico Bambin GesùRecruitingRetinitis Pigmentosa | Macular Dystrophy | Inherited Retinal DystrophyItaly
-
Children's Mercy Hospital Kansas CityRecruiting
-
Nanfang Hospital of Southern Medical UniversityFerring PharmaceuticalsUnknownDiminished Ovarian ReserveChina
-
Massachusetts General HospitalBroad Institute; Laboratory for Molecular MedicineCompletedGenetic Predisposition to Disease | Hereditary DiseaseUnited States